- Home
- CLPR vs LUNG Comparison
CLPR vs LUNG Comparison
Compare CLPR & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPR
- LUNG
- Stock Information
- Founded
- CLPR 2015
- LUNG 1995
- Country
- CLPR United States
- LUNG United States
- Employees
- CLPR N/A
- LUNG N/A
- Industry
- CLPR Real Estate Investment Trusts
- LUNG Industrial Specialties
- Sector
- CLPR Real Estate
- LUNG Health Care
- Exchange
- CLPR Nasdaq
- LUNG Nasdaq
- Market Cap
- CLPR 67.0M
- LUNG 63.6M
- IPO Year
- CLPR 2017
- LUNG 2020
- Fundamental
- Price
- CLPR $3.70
- LUNG $1.39
- Analyst Decision
- CLPR
- LUNG Buy
- Analyst Count
- CLPR 0
- LUNG 7
- Target Price
- CLPR N/A
- LUNG $6.81
- AVG Volume (30 Days)
- CLPR 53.2K
- LUNG 7.0M
- Earning Date
- CLPR 11-13-2025
- LUNG 11-12-2025
- Dividend Yield
- CLPR 10.38%
- LUNG N/A
- EPS Growth
- CLPR N/A
- LUNG N/A
- EPS
- CLPR N/A
- LUNG N/A
- Revenue
- CLPR $154,179,000.00
- LUNG $91,664,000.00
- Revenue This Year
- CLPR N/A
- LUNG $10.41
- Revenue Next Year
- CLPR N/A
- LUNG $10.98
- P/E Ratio
- CLPR N/A
- LUNG N/A
- Revenue Growth
- CLPR 5.90
- LUNG 15.59
- 52 Week Low
- CLPR $3.39
- LUNG $1.35
- 52 Week High
- CLPR $6.49
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- CLPR 43.07
- LUNG 39.44
- Support Level
- CLPR $3.66
- LUNG $1.35
- Resistance Level
- CLPR $3.86
- LUNG $2.11
- Average True Range (ATR)
- CLPR 0.16
- LUNG 0.17
- MACD
- CLPR -0.01
- LUNG -0.06
- Stochastic Oscillator
- CLPR 29.55
- LUNG 5.92
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.